Shares of CSL (ASX:CSL) fell almost 2% in recent trading on Thursday after Chairman Brian McNamee commented on the Australian government's efforts to avoid US tariffs on pharmaceuticals.
McNamee said that he doesn't think US President Donald Trump's demands are "unreasonable," and urged the government to make Australia's Pharmaceutical Benefits Scheme more efficient, The Australian reported Wednesday.
Australia could speed up the system for approvals and the mechanism for pricing of innovative new drugs, but this would "come at a cost," and the country would "need to make a contribution," he said.
Trump warned that the US could impose up to a 200% tariff on pharmaceuticals after a grace period of a year to 18 months.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。